Lineage Cell Therapeutics, Inc.
LCTX
$1.61
$0.031.90%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 102.86% | 2.24% | -636.02% | -26.46% | -7.88% |
| Total Depreciation and Amortization | 4.49% | 4.09% | 4.27% | 8.61% | 7.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -121.76% | 1.67% | 4,315.55% | -210.63% | -125.31% |
| Change in Net Operating Assets | 105.28% | 33.12% | -777.61% | 91.12% | 18.72% |
| Cash from Operations | -34.90% | 34.72% | -13.36% | 23.01% | -9.66% |
| Capital Expenditure | -3,225.00% | 14.29% | 85.57% | 73.42% | -225.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | -33.33% | -25.00% |
| Cash from Investing | -127,683.33% | 14.29% | -100.74% | -27.78% | -32.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 6.25% | -14.29% | 0.00% | 0.00% | -7.69% |
| Issuance of Common Stock | 879.59% | -- | -- | -75.83% | 219,090.00% |
| Repurchase of Common Stock | -- | 100.00% | -333.33% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -1.75% | -1.79% | -30.99% | -- |
| Cash from Financing | 1,011.18% | 697.39% | -106.09% | -76.79% | 724,566.67% |
| Foreign Exchange rate Adjustments | 4,600.00% | -101.37% | 501.37% | -392.00% | -34.21% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 119.30% | 67.70% | -380.03% | -88.98% | 1,068.24% |